Barclays PLC Purchases 30,093 Shares of Sera Prognostics, Inc. (NASDAQ:SERA)

Barclays PLC increased its position in shares of Sera Prognostics, Inc. (NASDAQ:SERA) by 321.6% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 39,450 shares of the company’s stock after purchasing an additional 30,093 shares during the period. Barclays PLC’s holdings in Sera Prognostics were worth $308,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently made changes to their positions in SERA. Bank of New York Mellon Corp increased its position in Sera Prognostics by 100.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 150,708 shares of the company’s stock valued at $892,000 after purchasing an additional 75,441 shares during the period. Quest Partners LLC increased its holdings in Sera Prognostics by 533.5% during the third quarter. Quest Partners LLC now owns 6,430 shares of the company’s stock valued at $50,000 after buying an additional 5,415 shares during the period. State Street Corp raised its stake in Sera Prognostics by 8.8% in the third quarter. State Street Corp now owns 425,093 shares of the company’s stock worth $3,316,000 after buying an additional 34,479 shares in the last quarter. American Century Companies Inc. lifted its holdings in Sera Prognostics by 12.7% during the second quarter. American Century Companies Inc. now owns 25,682 shares of the company’s stock worth $152,000 after buying an additional 2,891 shares during the period. Finally, Rhumbline Advisers bought a new stake in Sera Prognostics during the 2nd quarter valued at $190,000. 54.64% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CEO Zhenya Lindgardt sold 12,075 shares of the business’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $7.32, for a total transaction of $88,389.00. Following the transaction, the chief executive officer now directly owns 819,758 shares in the company, valued at $6,000,628.56. The trade was a 1.45 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Paul Kearney sold 4,078 shares of the stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $7.32, for a total value of $29,850.96. Following the completion of the sale, the insider now owns 176,889 shares of the company’s stock, valued at approximately $1,294,827.48. This trade represents a 2.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 28,250 shares of company stock worth $206,774 in the last 90 days. 15.80% of the stock is owned by corporate insiders.

Sera Prognostics Trading Down 3.7 %

Shares of NASDAQ:SERA opened at $8.02 on Friday. The company has a market capitalization of $270.85 million, a PE ratio of -8.10 and a beta of 0.92. Sera Prognostics, Inc. has a 12-month low of $4.90 and a 12-month high of $12.35. The business’s fifty day simple moving average is $7.47 and its 200-day simple moving average is $7.25.

Sera Prognostics (NASDAQ:SERA) last announced its earnings results on Wednesday, November 6th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.02). The business had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.09 million. During the same period in the previous year, the company earned ($0.23) EPS. Research analysts predict that Sera Prognostics, Inc. will post -0.96 EPS for the current year.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.